Antares Pharma, Inc. (ATRS) posted an all-time high at $5.58 in 2012 and entered a multi-wave downtrend that finally ended at 67-cents in the first quarter of 2016. The subsequent recovery lifted the stock back above broken 2014 support …
ATRS closed Thursday's trading at $3.73, down 5.33%. In after-hours, the stock was down 41.02% to $2.20. BioDelivery Sciences International Inc. (BDSI) has entered into a Settlement Agreement with Teva Pharmaceuticals Industries Ltd. …
If you want a Stock Review on ATRS, IART, BDX, or WAT then come over to http://dailystocktracker.com/register and …
If you want a Stock Review on BAX, ATRS, IART, or BDX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Research coverage has been initiated by DailyStockTracker.com on Baxter …
Antares Pharma Inc. (NASDAQ:ATRS) announced Thursday that the U.S. Food and Drug ... Antares submitted the Xyosted application in December 2016. Antares stock was up 60% this year, based on today's closing price, with the …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly ... http://investorplace.com/2014/06/4-medical-devices-stocks-to-buy-now-wwin-atrs-nvcn/.
A year ago, they were trading at $1.53. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATRS at https://www.zacks.com/ap/ATRS
The stock rallied 215 percent over Tuesday and Wednesday of this ... Equities Trading DOWN Antares Pharma Inc (NASDAQ: ATRS) shares dropped 41 percent to $2.21 after the company disclosed the receipt of an FDA letter that …